Protalix BioTherapeutics Inc.

NYSE American: PLX    
Share price (5/14/24): $1.16    
Market cap (5/14/24): $85.0 million
Search in Documents
Key Exhibits
External Links

Indentures Filter

EX-4.7
from 10-K 3 pages Description of Capital Stock
12/34/56
EX-4.7
from 10-K 3 pages Description of Capital Stock
12/34/56
EX-4.1
from S-8 17 pages Protalix Biotherapeutics, Inc. Amended and Restated 2006 Stock Incentive Plan, as Amended
12/34/56
EX-4.4
from S-3 56 pages Protalix Biotherapeutics, Inc., Issuer and , Trustee Indenture Dated as of ___, 202
12/34/56
EX-4.3
from S-3 55 pages Protalix Biotherapeutics, Inc., Issuer and , Trustee Indenture Dated as of ___, 202
12/34/56
EX-4.3
from 8-K 12 pages Principal Amount $28,750,000 as Revised by the Schedule of Increases and Decreases of Global Note Attached Hereto Protalix Biotherapeutics, Inc. 7.50% Senior Secured Convertible Notes Due 2024
12/34/56
EX-4.2
from 8-K 190 pages Protalix Biotherapeutics, Inc. as Issuer and Each of the Guarantors Party Hereto 7.50% Senior Secured Convertible Notes Due 2024 Indenture Dated as of August 24, 2021 the Bank of New York Mellon Trust Company, N.A. as Trustee Wilmington Savings Fund Society, Fsb ​ as Collateral Agent
12/34/56
EX-4.1
from 8-K 15 pages Third Supplemental Indenture ​
12/34/56
EX-4.9
from 10-Q 7 pages Option Agreement
12/34/56
EX-4.8
from 10-Q 7 pages Option Agreement
12/34/56
EX-4.1
from 8-K 12 pages Warrant to Purchase Shares of Common Stock of Protalix Biotherapeutics, Inc
12/34/56
EX-4.7
from 10-K 3 pages Description of Capital Stock
12/34/56
EX-4.4
from S-3 55 pages Protalix Biotherapeutics, Inc., Issuer and , Trustee Indenture Dated as of ___, 201
12/34/56
EX-4.3
from S-3 54 pages Protalix Biotherapeutics, Inc., Issuer and , Trustee Indenture Dated as of ___, 201
12/34/56
EX-4.1
from 8-K 5 pages Second Supplemental Indenture by and Among Protalix Biotherapeutics, Inc., as Issuer, and Each of the Guarantors Party Hereto, and the Bank of New York Mellon Trust Company, N.A., as Trustee, Dated as of November 27, 2017 to the Indenture, Dated as of December 7, 2016, as Supplemented by the First Supplemental Indenture, Dated as of July 24, 2017 Relating to 7.50% Senior Secured Convertible Notes Due 2021 Second Supplemental Indenture
12/34/56
EX-4.4
from 8-K 10 pages Form of Face of Note
12/34/56
EX-4.2
from 8-K 6 pages First Supplemental Indenture Between Protalix Biotherapeutics, Inc., as Issuer, and Each of the Guarantors Party Hereto, and the Bank of New York Mellon Trust Company, N.A., as Trustee, and Wilmington Savings Fund Society, Fsb, as Collateral Agent Dated as of July 24, 2017 to the Indenture, Dated as of December 7, 2016, Relating to 7.50% Senior Secured Convertible Notes Due 2021 First Supplemental Indenture
12/34/56
EX-4.1
from 8-K 86 pages Protalix Biotherapeutics, Inc. (Company) the Bank of New York Mellon Trust Company, N.A., as Trustee (Trustee) 4.50% Convertible Senior Notes Due 2022 Indenture Dated as of July 24, 2017
12/34/56
EX-4.3
from 8-K 12 pages Principal Amount $40,186,000 as Revised by the Schedule of Increases and Decreases of Global Note Attached Hereto Protalix Biotherapeutics, Inc. 7.50% Senior Secured Convertible Notes Due 2021
12/34/56
EX-4.2
from 8-K 13 pages This Is a Global Note Within the Meaning of the Indenture Hereinafter Referred to and Is Registered in the Name of the Depositary or a Nominee of the Depositary, Which May Be Treated by the Company, the Trustee and Any Agent Thereof as Owner and Holder of This Note for All Purposes
12/34/56